InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $163.58M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 3.05M
Average 1.80M
IFRX Common Stock Issued
Cash raised by issuing new shares.
InflaRx N.V.NASDAQ: IFRX
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow shrinks to €0
Q1 FY2026 common stock issued was €0, compared with €16.14M a year earlier. Trailing-twelve-month common stock issued was €16.2M. Over 3 fiscal years it compounded at +139.7% a year.
Context
- Common stock issued amounted to 110276.5% of revenue in FY2025, up 109614.0 pp from a year earlier.
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near €0 or moves back toward the trailing-twelve-month quarterly average of €4.05M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
EUR · from the cash flow
- Latest · FY2025
- 32.35M EUR
- Year-over-year change
- +2845.1%
- 4-year CAGR
- -16.1%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.35M | +2845.1% |
| FY2024 | 2024-12-31 | 1.1M | -98.1% |
| FY2023 | 2023-12-31 | 56.48M | +2304.0% |
| FY2022 | 2022-12-31 | 2.35M | -96.4% |
| FY2021 | 2021-12-31 | 65.14M | — |
Common Stock Issued vs competitors
How IFRX compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.0% is the 4th highest of 6, against a peer median of +5.6%.
- Common stock issued amounts to 55236.8% of revenue for IFRX, versus a peer median of 2164.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $103.37M USD | +5.6% | -81.2% | 103.8% | |
IMAImageneBio Inc | LTM Mar 2026 | $62.59M USD | — | — | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $50.07M USD | — | — | — |
| LTM Mar 2026 | $47.69M USD | -6.8% | +129.8% | 25101.6% | |
| LTM Mar 2026 | $26.22M USD | +2495.6% | +538.3% | 2621.6% | |
| LTM Mar 2026 | €16.2M EUR | -6.0% | +139.7% | 55236.8% | |
| FY2025 | $1.09M USD | +381.5% | +293.1% | 1707.8% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $131K USD | — | — | — |
| LTM Mar 2026 | $0 USD | -100.0% | -46.9% | — | |
| Peer median (excluding IFRX) | — | +5.6% | +129.8% | 2164.7% | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (43.83M) |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 402.93K |
| Deferred Income Tax | 1.16M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.33M | 6.04M | 3.41M | 4.07M | 0 |
| Change in Working Capital | 1.54M | (9.77M) | 1M | (2.28M) | 4.66M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 2.12M |
| Inventory | 0 | 0 | (11.37M) | 4.47M | 6.63M |
| Accounts Payables | 316.11K | (3.52M) | 0 | 0 | (5.76M) |
| Other Working Capital | 1.22M | (6.25M) | 12.37M | (6.75M) | 1.68M |
| Other Non-Cash Items | (2M) | (1.13M) | (131.29K) | (4.76M) | 4.84M |
| Operating Cash Flow | (39.94M) | (33.74M) | (37.81M) | (48.56M) | (33.92M) |
| Capital Expenditures | (37.78K) | (162.39K) | (81.1K) | (46.87K) | (111.13K) |
| Acquisitions (Net) | 37.78K | (19.52M) | 0 | 0 | 0 |
| Purchases of Investments | (97.52M) | (64.47M) | (104.05M) | (35.34M) | (44.28M) |
| Sales of Investments | 71.6M | 84M | 86.44M | 87.75M | 47.5M |
| Other Investing Activities | (37.78K) | 19.52M | 0 | 1 | (3) |
| Investing Cash Flow | (25.95M) | 19.36M | (17.7M) | 52.36M | 3.11M |
| Debt Repayment | (360.64K) | (364.43K) | (373.98K) | (388.11K) | (357.58K) |
| Common Stock Issued | 65.14M | 2.35M | 56.48M | 1.1M | 32.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.2M) | (47.74K) | (3.12M) | (323.73K) | 14.11K |
| Financing Cash Flow | 61.58M | 1.94M | 52.99M | 386.45K | 32M |
| Effect of Forex Changes | 4.59M | 2.46M | (974.1K) | 1.41M | (1.37M) |
| Net Change in Cash | 281.31K | (9.98M) | (3.5M) | 5.61M | (179.66K) |
| Free Cash Flow | (39.97M) | (33.91M) | (37.89M) | (48.6M) | (34.03M) |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.